These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Arrival of Norplant may be bittersweet for clinics.
    Journal: Contracept Technol Update; 1991 Jan; 12(1):1-6. PubMed ID: 12283523.
    Abstract:
    While the approval of NORPLANT in the US now offers women an effective reversible contraceptive, public health clinics will face several obstacles in providing the new method--especially cost. Wyeth-Ayerst Laboratories, the company marketing NORPLANT, has yet to disclose the price for the new contraceptive, but experts believe that it will be at least $300 per set of implants. Adding the price of insertion, NORPLANT could cost over $500. Planned Parenthood officials say that this will make it far too expensive for public clinics, which currently obtain contraceptives at less than retail cost. Individual, women will also face the high price, since most insurance companies don't cover the cost of contraceptives. Another problem facing the introduction of NORPLANT is the bleeding irregularities most women experience under the new method, especially during the first year. One study of NORPLANT reported that out of 200 women, 17% chose to discontinue the treatment because of bleeding changes. Wyeth-Ayerst's own label indicates that out of 849 women who discontinued use during the first year, 75% did so because of bleeding irregularities. An additional problem with NORPLANT is that clinicians will have to undergo intensive training on the insertion and, more importantly, removal of the implants. Currently there's only a limited number of training sites in the country.
    [Abstract] [Full Text] [Related] [New Search]